This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

uniQure N.V.
11/4/2026
Hello and thank you for standing by. My name is John and I will be your conference operator today. At this time, I would like to welcome everyone to the Unique Year 3rd Quarter 2026 earnings call. All lines have been placed on view to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number 1 on your telephone keypad. If you would like to withdraw your question, press star 1 again. Thank you. I would like to turn the call over to Chiara Russo, Senior Director of Investor Relations.
Thank you. Good morning, and thank you for joining us for Unicare's third quarter of 2026 earnings call. Earlier this morning, Unicare released its financial results for the third quarter of 2026, and our press release is available on the Investors and Media section of our website at unicare.com. Our 10-Q was also filed with the SEC earlier today. Joining me on the call this morning are Matt Kapusta, Chief Executive Officer, Dr. Walid Abi-Saab, Chief Medical Officer, Kylie O'Keefe, Chief Customer and Strategy Officer, and Christian Klemt, Chief Financial Officer. After our formal remarks, we'll open up for an analyst Q&A. Before we begin, Please know that we will be making forward-looking statements during this investor call. All statements, other than statements of historical fact, are forward-looking statements. They are based on management's beliefs and assumptions and on information available to management only as of the date of this conference call. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including without limitation the factors described in Unicure's most recent SEC filings. Given these risks, we should not place undue reliance on these forward-looking statements, and we assume no obligation to update these statements, even if information becomes available in the future. Now, let me introduce Matt Kapusta, Unicare's CEO.
Thanks, Chiara. Good morning, and thank you for joining us on today's call. For the families who avoid degeneration for treatment for Huntington's disease, this quarter brought meaningful progress. As we announced Monday, The FDA has accepted our biologics license application for AM2130 and granted priority review with a target PDUFA date of May 1, 2027. In the United Kingdom, the MHRA has also validated our marketing authorization application. These are the first such marketing applications for disease-modifying therapy for Huntington's disease, and it brings patients and families one step closer to a treatment option. We greatly appreciate the engagement of both the FDA and the MHRA and their focus on the critical need for new therapies and Huntington's disease. I also want to acknowledge the commitment of our clinical, regulatory, and CMC teams who prepared and submitted both applications in record time. And to every HD patient, family member, and investigator who has trusted us with their hope, thank you. In September, we shared additional data from our ongoing Phase 1-2 studies including updated 36-month data from all 27 valuable patients across the low- and high-dose cohorts and, for the first time, 48 months of follow-up after a single administration of AMT130. These data continue to show meaningful dose-dependent slowing of disease progression and reinforce our strong belief that AMT130 has the potential to deliver treatment benefit to patients. We are also pleased to have aligned with the FDA on the key elements of the confirmatory study design, and we are making significant progress getting the trial up and running. We are fully committed to the timely execution of this study, and our priority is to have it well underway at the time of an approval decision. Walid will provide more detail on the confirmatory study later in the call. Regarding commercial preparations, we are making excellent progress ahead of potential US launch in 2027. We continue to build out our field, medical, market access, and strategic account teams in a disciplined way, and our financial strength provides the runway needed to execute this build-out. Kylie and Christian will provide more details on our commercial readiness and financial position later on the call. Beyond AMT-130, we continue to advance our broader pipeline. We've completed enrollment in the second-dose cohort of our Phase I two-way study of AMT-260 and refractory, Mesial Temporal Lobe Epilepsy, and have resumed enrollment in the Phase 1-2 study of AMT191 and Fabry disease. For both programs, we expect to present new and updated data in the first half of 2027. In summary, we are heading into the end of 2026 with strong momentum. Our priorities are clear. Working closely with regulators as the application reviews proceed, executing our confirmatory study, advancing our pipeline, and building the organization to prepare for the planned launch of AMT-130. With that, I will turn the call over to Walid to provide additional detail on AMT-130 in our pipeline. Walid?
You're reading a preview of the QURE Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing